文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

急性肾损伤与SARS-CoV-2感染严重程度及死亡率的关联:一项Meta分析

Association of acute kidney injury with the severity and mortality of SARS-CoV-2 infection: A meta-analysis.
PubMed 文献 · Am J Emerg Med · 2020-09-02
一句话结论COVID-19合并AKI与疾病严重程度和死亡风险显著相关,重症患者AKI患病率OR为13.16,非存活者OR为77.48,应重视AKI风险筛查与早期识别。

该Meta分析纳入41项研究共10335例COVID-19患者,比较重症与非重症、存活与非存活患者肾功能指标及AKI发生率。重症患者sCr、BUN、血尿、蛋白尿均显著高于非重症,eGFR显著降低,CRRT和AKI患病率OR分别为12.99和13.16;非存活患者sCr和BUN显著升高,CRRT和AKI患病率OR分别为31.51和77.48。结论提示AKI与COVID-19严重程度和死亡率密切相关,应加强风险筛查、早期识别和及时治疗。

要点

  • 重症vs非重症COVID-19患者AKI患病率OR=13.16(95%CI 10.16-17.05),CRRT使用OR=12.99(95%CI 4.03-41.89)。
  • 非存活vs存活COVID-19患者AKI患病率OR=77.48(95%CI 24.52-244.85),CRRT使用OR=31.51(95%CI 6.55-151.59)。
  • 重症患者sCr(SMD=0.34,95%CI 0.29-0.39)、BUN(SMD=0.66,95%CI 0.51-0.81)、血尿(OR=1.59,95%CI 1.15-2.19)、蛋白尿(OR=2.92,95%CI 1.58-5.38)均显著高于非重症。
  • 重症患者eGFR较非重症显著降低(SMD=-0.45,95%CI -0.67至-0.23)。
  • 非存活患者sCr(SMD=0.97)和BUN(SMD=1.49)较存活患者显著升高。

适用人群与场景

  • COVID-19(SARS-CoV-2感染)患者,涵盖重症与非重症、存活与非存活人群的Meta分析,共纳入41项研究10335例患者进行严重程度分析,11项研究3759例患者进行死亡率分析。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:系统评价与Meta分析,检索PubMed、EMBASE、Scopus、Web of Science、MedRxiv Database。
  • 严重程度分析纳入41项研究共10335例COVID-19患者;死亡率分析纳入11项研究共3759例COVID-19患者。
  • 重症vs非重症:sCr SMD=0.34(95%CI 0.29-0.39),BUN SMD=0.66(95%CI 0.51-0.81),血尿OR=1.59(95%CI 1.15-2.19),蛋白尿OR=2.92(95%CI 1.58-5.38),eGFR SMD=-0.45(95%CI -0.67至-0.23),CRRT OR=12.99(95%CI 4.03-41.89),AKI患病率OR=13.16(95%CI 10.16-17.0
  • 非存活vs存活:sCr SMD=0.97,BUN SMD=1.49,CRRT OR=31.51(95%CI 6.55-151.59),AKI患病率OR=77.48(95%CI 24.52-244.85)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析。
  • 原文未述推荐等级。
  • 原文未述局限性。

对床旁实践的改变

  • 提示医生对COVID-19患者应重视AKI的风险筛查、早期识别和及时治疗。
  • AKI与COVID-19严重程度和死亡率密切相关,重症及非存活患者中AKI患病率和CRRT使用率显著更高。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: we aimed to explore the relationship of acute kidney injury (AKI) with the severity and mortality of coronavirus disease 2019 (COVID-19).

METHODS: A systematic literature search was conducted in PubMed, EMBASE, Scopus, Web of Science, MedRxiv Database. We compared the laboratory indicators of renal impairment and incidences of AKI in the severe versus non-severe cases, and survival versus non-survival cases, respectively.

RESULTS: In 41 studies with 10,335 COVID-19 patients, the serum creatinine (sCr) in severe cases was much higher than that in non-severe cases (SMD = 0.34, 95% CI: 0.29-0.39), with a similar trend for blood urea nitrogen (BUN) (SMD = 0.66, 95%CI: 0.51-0.81), hematuria (OR = 1.59, 95% CI: 1.15-2.19), and proteinuria (OR = 2.92, 95% CI: 1.58-5.38). The estimated glomerular filtration rate decreased significantly in severe cases compared with non-severe cases (SMD = -0.45, 95% CI: -0.67- -0.23). Moreover, the pooled OR of continuous renal replacement therapy (CRRT) and AKI prevalence for severe vs. non-severe cases was 12.99 (95%CI: 4.03-41.89) and 13.16 (95%CI: 10.16-17.05), respectively. Additionally, 11 studies with 3759 COVID-19 patients were included for analysis of disease mortality. The results showed the levels of sCr and BUN in non-survival cases remarkably elevated compared with survival patients, respectively (SMD = 0.97, SMD = 1.49). The pooled OR of CRRT and AKI prevalence for non-survival vs. survival cases was 31.51 (95%CI: 6.55-151.59) and 77.48 (95%CI: 24.52-244.85), respectively.

CONCLUSIONS: AKI is closely related with severity and mortality of COVID-19, which gives awareness for doctors to pay more attention for risk screening, early identification and timely treatment of AKI.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Ouyang L, Gong Y, Zhu Y, et al. Association of acute kidney injury with the severity and mortality of SARS-CoV-2 infection: A meta-analysis. Am J Emerg Med. 2020. PMID: 33046323. doi:10.1016/j.ajem.2020.08.089

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。